Previous studies reported that serum sclerostin gradually increases from non-uremic controls without overt calcification-related cardiovascular disease to those with AVC, and from uremic patients without AVC to their counterparts with AVC [13, 15]. This evidence concerns the gene SOST and cardiovascular disorder.